This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PDL BioPharma's CEO Discusses Q1 2012 Results - Earnings Call Transcript

I’ll now turn the call over to John McLaughlin, President and CEO of PDL BioPharma.

John McLaughlin

Thanks, Jennifer, and good afternoon everyone. Also with me today is Caroline Krumel Vice President of Finance. As always in this call, I’ll provide a summary of recent events and an overview of our financial results from the quarter.

As you can see in slide three, we were very pleased to announce last week that Bruce Tomlinson will be joining us as Vice President, CFO. Bruce joined us from InterMune, a public biopharmaceutical company where he was Chief Accounting Officer, Vice President of Finance and Corporate Controller. Bruce managed all accounting and treasury functions, financial reporting, systems and controls and Sarbanes-Oxley Compliance at InterMune.

He brings more than 20 years of financial and management experience which is very relevant to PDL including knowledge of convertible debt transactions and tax structures. He will join us here in Incline Village on June 11 th and we will be happy to have him on board and know that you’ll be talking with him in the months ahead.

Turning to our financial results on slide four, total revenues for the first quarter of 2012 were $77.3 million compared to $83.3 million for the first quarter of 2011. As we noted in the press release, total revenue for 2012 included a $10 million settlement payment from UCB Pharma resolving all disputes between our two companies. Excluding the UCB payment, royalty revenue increased a little over 5%.

Royalty revenues for the first quarter of 2012 are based on fourth quarter 2011 sales by PDLs licensees. The growth in revenue for the first quarter of 2012 is primarily driven by increased royalties on sales of Herceptin, which is marketed by Genentech and Roche, Lucentis and Xolair both of which are marketed by Genentech and Novartis, and Tysabri which is marketed by Elan and Biogen Idec. Royalty revenue for the first quarter is net of payments made under our February 2011 settlement agreement with Novartis.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs